WO2006042441A2 - Novel agents for preventing and treating disorders connected to impaired neurotransmission - Google Patents

Novel agents for preventing and treating disorders connected to impaired neurotransmission Download PDF

Info

Publication number
WO2006042441A2
WO2006042441A2 PCT/CH2005/000621 CH2005000621W WO2006042441A2 WO 2006042441 A2 WO2006042441 A2 WO 2006042441A2 CH 2005000621 W CH2005000621 W CH 2005000621W WO 2006042441 A2 WO2006042441 A2 WO 2006042441A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
coumarin
obliquin
coumarin ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2005/000621
Other languages
French (fr)
Other versions
WO2006042441A3 (en
Inventor
Antoine De Saizieu
Ann Fowler
Regina Goralczyk
Bernd Mussler
Goede Schueler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to JP2007537097A priority Critical patent/JP2008517879A/en
Priority to US11/665,072 priority patent/US8044094B2/en
Priority to DE602005012132T priority patent/DE602005012132D1/en
Priority to EP05794149A priority patent/EP1802298B1/en
Publication of WO2006042441A2 publication Critical patent/WO2006042441A2/en
Publication of WO2006042441A3 publication Critical patent/WO2006042441A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Novel agents for preventing and treating disorders connected to impaired neurotransmis ⁇ sion Novel agents for preventing and treating disorders connected to impaired neurotransmis ⁇ sion
  • the present invention refers to coumarin. ethers for use as medicaments, especially for the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant materials and extracts containing such coumarin ethers and their uses.
  • Neurotransmitters, drugs and brain function R.A. Webster (ed), John Wiley & Sons, New York, 2001, p. 187-211, 289-452, 477-498).
  • Increase in neurotrans ⁇ mission is achieved by increasing the concentration of the neurotransmitter in the synaptic cleft thus making it available for increased or prolonged neurotransmission through inhibi- tion of re-uptake into the pre-synaptic nerve end, or by preventing neurotransmitter catabo- lism by inhibition of degrading enzymes such as monoaminooxidase A and B.
  • Tricyclic antidepressant compounds such as imipramine, amitriptyline, and clomipramine e.g. inhibit the re-uptake of serotonin and noradrenaline. They are widely regarded as among the most effective antidepressants available, but they have a number of disadvantages because they interact with a number of brain receptors, e.g. with cholinergic receptors. Most importantly, TCAs are not safe when taken in overdose, frequently show ⁇ ing acute cardiotoxicity.
  • SSRIs selective serotonin re ⁇ uptake inhibitors
  • fluoxetine serotonin re ⁇ uptake inhibitors
  • paroxetine sertraline
  • citalopram fluvoxamine
  • Best&tfgungskop ⁇ block the serotonin transporter (SERT), a high affinity sodium chloride-dependent neuro ⁇ transmitter transporter that terminates serotonergic neurotransmission by uptake of sero ⁇ tonin. They have been proven as effective in the treatment of depression and anxiety, and are usually better tolerated than TCAs. These medications are typically started at low dos- ages and may be increased until they reach a therapeutic level. A common side effect is nausea. Other possible side effects include decreased appetite, dry mouth, sweating, infec ⁇ tion, constipation, yawn, tremor, sleepiness and sexual dysfunction.
  • MAOs monoaminooxidases
  • modulators of neurotransmission exert pleiotropic effects on mental and cog- nitive functions.
  • R 1 is H, OH or (E)-3-methyl-but-2-enyl
  • R 2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7- dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11- acetyloxy-SJJlJl-tetramethyl-undeca ⁇ J-dien-lO-on-yl
  • the invention relates to the use of a coumarin ether of the formula I as defined above for the manufacture of a composition for the treatment of a disorder con ⁇ nected to impaired neurotransmission, particularly for the manufacture of an antidepres ⁇ sant, a mood improver, a stress reliever, a condition improver, a reducer of anxiety and/or a reducer of obsessive-compulsive behaviour.
  • the invention relates to a dietary composition containing at least one coumarin ether of the formula I as defined above as well as to a pharmaceutical composi ⁇ tion containing at least one coumarin ether of the formula I as defined above and a conven ⁇ tional pharmaceutical carrier.
  • the invention relates to a method for the treatment of a disorder connected to im ⁇ paired neurotransmission in animals including humans, said method comprising adminis ⁇ tering an effective dose of a coumarin ether of the formula I as defined above to animals including humans which are in need thereof.
  • Animals in the context of the present invention include humans and encompass mammals, fish and birds.
  • Preferred "animals" are humans, pet animals and farm animals. Examples for pet animals are dogs, cats, birds, toy fish, guinea pigs, (jack) rabbits, hares and ferrets. Examples for farm animals are fish, pigs, horses, ruminants (cattle, sheep and goat) and poultry.
  • the coumarin ether of the formula I is selected from the group consisting of obliquin (compound of the formula It; see Fig. 1), xanthyletin (compound of the formula HI; see Fig. 1), suberosin (compound of the formula IV; see Fig. 1), 7-geranyloxycoumarm (compound of the formula V; see Fig. 1), ⁇ '-dehydromarmin (compound of the formula VI; see Fig. 1), geiparvarin (compound of the formula VHI; see Fig. 1), O-acetylcolumbianetin (compound of the formula IX; see Fig. 1) and the com ⁇ pound of the formula VQ (see Fig. 1). More preferably the coumarin ether of the formula I is obliquin, most preferably the coumarin ether of the formula I is (5)-obliquin.
  • coumarin ether of the formula I also encompasses any material or extract of a plant containing such a coumarin ether of the formula I, especially any material or extract of a plant containing at least 90 weight-% of such a coumarin ether of the formula I based on the total weight of the plant material or extract.
  • material of a plant and “plant material” used in the context of the present invention mean any part of a plant.
  • Obliquin means the racemic mixture as well as pure R-obliquin or pure S-obliquin or any mixture of them. Obliquin can be isolated from plants like, but not limited to, Cedrelopsis grevei, Ptaeroxylon obliquum, Leontopodium alpinum, Helichrysum ssp., Ifloga spicata, Nidorella anomala, Cneorum tricoccum, Phaenocoma prolifera and Cedrelopsis microfo- liata (Journal of Natural Products 2002, 65, 1349-1352).
  • any material or extract of these plants or any other plant material or extract con ⁇ taining obliquin is also encompassed by this expression.
  • "Obliquin” means both "natural” (isolated) and “synthetic” (manufactured) obliquin.
  • 7-Geranyloxycoumarin also called “aurapten” can be isolated from plants like the follow ⁇ ing, but not limited to Citrus ssp., Aegle martnelos, Poncirus trifoliata, Afraegle panicu- lata, Severinia buxifolia, Atalantia monophylla, Ptelea trifoliata and Fortunella hindsii. Therefore, any material or extract of these plants or any other plant material or extract con ⁇ taining 7-geranyloxycoumarin is also encompassed by this expression.
  • “7-Geranyloxy- coumarin” means both "natural” (isolated) and “synthetic” (manufactured) 7-geranyloxy ⁇ coumarin.
  • Suberosin can be isolated from plants like the following, but not limited to Plumbago zey- lanica, Seseli ssp., Heracleum candicans, Citrus ssp., Prangos lipskyi and Prangos lo- phoptera. Therefore, any material or extract of these plants or any other plant material or extract containing suberosin is also encompassed by this expression.
  • “Suberosin” means both "natural” (isolated) and “synthetic” (manufactured) suberosin.
  • the compound of formula VII (CAS [374702-57-5]) can be isolated from Ferula tadshi- korum and other plants. Therefore, any material or extract of these plants or any other plant material or extract containing the compound of formula VII is also encompassed by this expression.
  • “Compound of formula VH” means both "natural” (isolated) and “synthetic” (manufactured).
  • 6 * -Dehydromarrnin can be isolated from the fruit of Geijera parviflora and other plants. Therefore, any material or extract of these plants or any other plant material or extract con ⁇ taining 6'-dehydromarmin is also encompassed by this expression.
  • 6'-Dehydromarmin means both "natural” (isolated) and “synthetic” (manufactured) 6'-dehydromarmin.
  • Geiparvarin can be isolated from the leaves of Geijera parviflora and other plants. There- fore, any material or extract of these plants or any other plant material or extract containing geiparvarin is also encompassed by this expression.
  • Geiparvarin means both "natural” (isolated) and “synthetic” (manufactured) geiparvarin.
  • Geiparvarin can be prepared according to the process described in Journal of Organic Chemistry 1985, 50(21), 3997-4005 or in Bioorganic & Medicinal Chemistry Letters 2002, 12(24), 3551-3555.
  • O-Acetylcolu ⁇ ibianetin can be isolated from plants like, but not limited to Cnidium monnieri and Angelica ssp. Therefore, any material or extract of these plants is also en ⁇ compassed by this expression.
  • O-Acetylcolumbianetin means both "natural” (isolated) and “synthetic” (manufactured) O-acetylcolumbianetin.
  • the dietary compositions according to the present invention may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsi- fiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (sol ⁇ vents), flowing agents, taste masking agents, weighting agents, jellyfying agents, gel form ⁇ ing agents, antioxidants and antimicrobials.
  • protective hydrocolloids such as gums, proteins, modified starches
  • binders film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsi- fiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents
  • dietary compositions comprises any type of nutrition such as (fortified) food/feed and beverages including also clinical nutrition, and also dietary supplements.
  • the pharmaceu ⁇ tical compositions according to the present invention may further contain conventional pharmaceutical additives and adjuvants, excipients or diluents, including, but not limited to, water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
  • the carrier material can be organic or inorganic inert carrier material suitable for oral/paren- teral/injectat ⁇ e administration.
  • the dietary and pharmaceutical compositions according to the present invention may be in any galenic form that is suitable for administrating to the animal body including the human body, especially in any form that is conventional for oral administration, e.g. in solid form such as (additives/supplements for) food or feed, food or feed premix, fortified food or feed, tablets, pills, granules, dragees, capsules, and effervescent formulations such as pow ⁇ ders and tablets, or in liquid form such as solutions, emulsions or suspensions as e.g. bev ⁇ erages, pastes and oily suspensions.
  • the pastes may be filled into hard or soft shell cap- sules, whereby the capsules feature e.g.
  • a matrix of (fish, swine, poultry, cow) gelatin, plant proteins or ligninsulfonate examples are forms for trans ⁇ dermal, parenteral or injectable administration.
  • the dietary and pharmaceutical composi ⁇ tions may be in the form of controlled (delayed) release formulations.
  • Examples of food are dairy products such as yoghurts.
  • Examples of fortified food are cereal bars, bakery items such as cakes and cookies.
  • Beverages encompass non-alcoholic and alcoholic drinks as well as liquid preparations to be added to drinking water and liquid food.
  • Non-alcoholic drinks are e.g. soft drinks, sport drinks, fruit juices, lemonades, teas and milk based drinks.
  • Liquid food are e.g. soups and dairy products (e.g. muesli drinks).
  • the coumarin ethers of formula I with the definitions of R 1 , R 2 and R 3 and the preferences as given above can be used for the manufacture of medicaments for the treatment of a dis ⁇ order connected to impaired neurotransmission.
  • treatment also encompasses co-treatment as well as prevention.
  • prevention can be the prevention of the first occurrence (primary prevention) or the prevention of a reoccurence (secondary prevention).
  • the present invention is also directed to a method for the prevention of a disorder connected to impaired neurotransmission in animals including humans, said method com ⁇ prising administering an effective dose of a coumarin ether of the formula I with the defini ⁇ tions of R 1 , R 2 and R 3 and the preferences as given above to animals including humans which are in need thereof.
  • an effective dose of a coumarin ether of the for- mula I with the definitions of R 1 , R 2 and R 3 and the preferences as given above may espe ⁇ cially be used for maintaining the mental well-being, for maintaining a balanced cognitive function, for helping to reduce the risk of mood swings, for helping to retain a positive mood and for supporting cognitive wellness.
  • disorders also encompasses diseases.
  • Antidepressants are medicaments for treating mental, behavioural and emotional/affective, neurotic, neurodegenerative, eating and stress related disorders such as e.g. unipolar de- pression, bipolar depression, acute depression, chronic depression, subchronic depression, dysthymia, postpartum depression, premenstrual dysphoria/syndrom (PMS), climacteric depressive symptoms, aggression, attention deficit disorders (ADS), social anxiety disor ⁇ ders, seasonal affective disorders, anxiety (disorders), fibromyalgia syndrome, chronic fa ⁇ tigue, sleep disorders (insomnia), post-traumatic stress disorders, panic disorders, obses- sive compulsive disorders, restless leg syndrome, nervousness, migraine/primary head ⁇ aches and pain in general, emesis, bulimia, anorexia nervosa, binge eating disorder, gastro ⁇ intestinal disorders, burn out syndrome, irritability and tiredness.
  • unipolar de- pression bipolar depression, acute depression
  • Antidepressants can also be used for (the manufacture of compositions for) primary and secondary prevention and/or the treatment of neurocognitive impairment. Furthermore they are also effective in the treatment of depressive symptoms or other symptoms related to disturbed neurotransmission occurring as comorbidity in chronic diseases such as cardio- vascular diseases, strokes, cancer, Alzheimer disease, Parkinson disease, and others.
  • the coumarin ethers of the formula I with the definitions of R 1 , R 2 and R 3 and the prefer ⁇ ences as given above as well as plant materials and plant extracts (essentially) containing them and dietary/pharmaceutical compositions containing them are thus suitable for the treatment of animals including humans.
  • Especially pet animals and farm animals can be in conditions in need of enhanced or im ⁇ proved neurotransmission.
  • Such conditions e.g. occur after capture or transport or with housing, when the animals develop analogous disorders and are distressed or aggressive, or display stereotypic behaviour, or anxiety and obsessive-compulsive behaviour.
  • the coumarin ethers of the formula I with the definitions of R , R and R and the preferences as given above can be used in general as antidepressants for animals including humans, preferably for humans, pet animals and farm animals.
  • the coumarin ethers of the formula I with the definitions of R 1 , R 2 and R 3 and the preferences as given above find use as mood im ⁇ prover in general as well as for the manufacture of compositions for such use (plant mate ⁇ rials/extracts; dietary/pharmaceutical compositions).
  • “Mood improver” or “emotional well- ness booster” means that the mood of a person treated with it is enhanced, that the self es ⁇ teem is increased and/or that negative thoughts and/or negative tension are/is reduced. It also means the emotions are balanced and/or that the general, especially the mental, well being is improved or maintained, as well as that the risk of mood swings is (helped to be) reduced and that the positive mood is (helped to be) retained.
  • compositions comprising an effective dose of them are useful for the treatment, prevention and the alleviation of stress related symptoms, for the treatment, prevention and alleviation of symptoms related to working overload, exhaus- tion and/or burn out, for the increase of the resistance or tolerance to stress and/or to favor and facilitate the relaxation in normal healthy individuals i.e. such compositions have an effect as "stress reliever".
  • coumarin ethers of the formula I with the definitions of R , R and R and the preferences as given above as well as compositions comprising an effective dose of them are useful for the treatment, prevention and alleviation of anxiety and obsessive- compulsive behaviour in humans and animals.
  • a further embodiment of the present invention relates to the use of coumarin ethers of the formula I with the definitions of R 1 , R 2 and R 3 and the preferences as given above and to the use of compositions containing them (plant extracts; dietary/pharmaceutical composi ⁇ tions) as "condition improver", i.e. as means to reduce irritability and tiredness, to reduce or prevent or alleviate physical and mental fatigue, to favour undisturbed sleep, that is to act against insomnia and sleep disorders and to improve sleep, and to increase energy in more general terms, especially to increase the brain energy production, in diseased or nor ⁇ mal healthy individuals.
  • condition improver i.e. as means to reduce irritability and tiredness, to reduce or prevent or alleviate physical and mental fatigue, to favour undisturbed sleep, that is to act against insomnia and sleep disorders and to improve sleep, and to increase energy in more general terms, especially to increase the brain energy production, in diseased or nor ⁇ mal healthy individuals.
  • cognition improvement in general, and especially for maintenance or improvement of attention and concentration of the memory and of the capacity for remembering, of the learning ability, of the language processing, of problem solving and of intellectual functioning; for improvement of the short-term memory; for in ⁇ creasing the mental alertness; for enhancing the mental vigilance; for reducing the mental fatigue; for supporting cognitive wellness, for maintaining balanced cognitive function, for the regulation of hunger and satiety as well as for the regulation of motor activity.
  • the present invention not only refers to coumarin ethers of the formula I with the defini ⁇ tions of R 1 , R 2 and R 3 and the preferences as given above and their compositions (i.e. plant extracts essentially containing them; dietary/pharmaceutical compositions containing them) for use as medicaments, especially for the treatment of disorders connected to im ⁇ paired neurotransmission, but also for the methods for the treatment of such disorders themselves, as already mentioned above.
  • pet animals or farm animals whose disorders are associated with housing, capture or transport are treated and which may ap ⁇ pear in form of anxiety or obsessive-compulsive behaviour.
  • a suitable daily dosage of a coumarin ether of the formula I may be within the range from 0.001 mg per kg body weight to about 20 mg per leg body weight per day. More preferred is a daily dosage of about 0.01 to about 10 mg per kg body weight, and especially preferred is a daily dosage of about 0.05 to 5.0 mg per kg body weight.
  • the amount of a plant material or plant extract containing such coumarin ether of the formula I can be calculated accordingly.
  • the coumarin ether of the formula I is suitably present in an amount from about 0.1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg per dosage unit.
  • the coumarin ether of the formula I is suitably present in an amount of from about 0.0001 (1 mg/kg) to about 5 weight-% (50 g/kg), preferably from about 0.001 % (10 mg/kg)to about 1 weight-%, (10 g/kg) more pref ⁇ erably from about 0.01 (100 mg/kg) to about 0.5 weight-% (5 g/kg), based upon the total weight of the food or beverage.
  • the amount of the coumarin ether of the formula I with the definitions of R 1 , R 2 and R 3 and the preferences as given above is 10 to 30 mg per serving, i.e. 120 mg per kg food or drink.
  • a suitable daily dosage of a coumarin ether of the formula I may be within the range from 0.001 mg per kg body weight to about 1000 mg per kg body weight per day. More preferred is a daily dosage of about 0.1 mg to about 500 mg per kg body weight, and especially preferred is a daily dosage of about 1 mg to 100 mg per kg body weight.
  • Example 1 a racemic mixture of obliquin obtained from MicroSource Discovery Sys ⁇ tems Inc, 21 George Washington Plaza, Gaylordsville, CT 06755 USA was used. It had a purity of > 96%.
  • examples 2 and 3 a racemic mixture of obliquin synthesized according to J. Chem. Soc. (C) 1969, 526-531 was used. Xanthyletin were obtained from Micro- source as well. 7-geranyloxycoumarin, 6'-dehydromarmin, geiparvarin, (iS)-O-acetylcolum- bianetin and suberosin were obtained from APIN Chemicals, 43d Milton Park, Abingdon, Oxon, OX14 4RU, United Kingdom. And the compound of the formula VII was obtained from InterBioScreen Ltd., Bistitutsky Prospect, 7a 142432 Chernogolovka, Russia.
  • Example 1 Serotonin uptake inhibition and labeled citalopram displacement by coumarin ethers of the formula I.
  • HEK-293 cells stably expressing the human serotonin re-uptake transporter (hSERT) were obtained from R. Blakely, Vanderbilt University, USA. The cells were routinely grown in Dulbeco's Modified Eagles Medium, purchased from Bioconcept, Allschwil, Switzerland containing 10% fetal calf serum, penicillin, streptomycin, L-glutamine and the antibiotic G418 and passaged by trypsinisation.l day prior to the assay cells were seeded in the above mentioned medium.
  • Membranes containing hSERT were prepared from the above cell line according to Galli et al, Journal of Experimental Biology 1995, 198, 2197-2212. 3 ⁇ g of membrane protein and 0.8 mg of wheat germ aglutinin coated SPA® (scintillation proximity assay) beads (Amer ⁇ sham Biosciences GE Healthcare, Slough, UK) per data point were mixed with radio ⁇ labeled (3H) citalopram (Amersham Biosciences GE Healthcare, Slough, UK) until a final concentration of 3.3 nM in 5OmM Tris-HCl, 300 mM NaCl (pH 7.4). After incubation for 18 hours at room temperature, the bound citalopram was quantified by liquid scintillation counting.
  • the effect of the coumarin ethers of formula I on the serotonin uptake and the citalopram binding was determined by its inclusion in the assay at a range of concentrations between 0.03 and 100 ⁇ M for 10 minutes prior to and during the addition of (3H) serotonin / citalo ⁇ pram. Serotonin uptake via the transporter and citalopram binding were both inhibited by the coumarin ethers of formula I in a dose dependent manner.
  • the calculated inhibition constants Kj derived from the measured IC50 using the Cheng - Prusoff equation (Y.C. Cheng, W.H. Prusoff, Biochem. Pharmacol. 1973, 22, p. 3099 - 3108), for inhibition of serotonin uptake and citalopram binding by coumarin ethers of the formula I are shown in Table 1.
  • Table 1 Inhibition constants for inhibition of serotonin uptake into transfected HEK-293 cells and displacement of labeled citalopram from hSERT containing membranes by cou ⁇ marin ethers of formula I.
  • Example 2 Monoaminooxidase inhibition by obliquin.
  • MAO-A enzyme As substrates for MAO-A enzyme (Sigma Nr. M7316) p-tyramine and as substrate for MAO-B enzyme (Sigma Nr. M7441) benzylamine were used.
  • concentration of MAO- A enzyme was 8 Units/ml, and that of MAO-B 4 Units/ml in the working solution.
  • Table 2 Inhibition of MAO-A with increasing concentrations of obliquin.
  • the "Behavioural Despair Test” or “Porsolt's Forced Swim Test” is a validated animal model for depression (see T. Nagatsu, NeuroToxicology 2004, 25, 11-20, especially p. 16, right column in the middle, in combination with Porsolt et al., Arch. Int. Pharmacodyn. 1977, 229, 327-336). It responds to enhancement of the transmission of several neuro ⁇ transmitters including serotonine, dopamine and noradrenaline.
  • mice were studied per each of the four groups.
  • the test was performed blind, i.e. the person carrying out the experiment was different from the person injecting the mice and didn't thus know to which of the four groups each mouse belonged.
  • Obliquin was evaluated at 3 doses each: at 10, 30, and 80mg/kg body weight, administered intraperitonally 30 minutes before the test, and compared with a control group.
  • the thus administered obliquin was dissolved in a saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 (so called "vehicle").
  • vehicle consist- ing of the saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 was administered intraperitonally.
  • Example 4 Marble Burying Test as test for anxiety like or obsessive compulsive behaviour
  • SSRIs e.g. fluvoxamine, fluoxetine, citalopram
  • tricyclic antidepressants e.g. imipramine, desipramine
  • selective noradrenaline uptake inhibitors e.g. reboxetine
  • the model may reflect either anxiety-like-or obsessive-compulsive- behaviour (see De Boer and Koolhaas, Euro- pean Journal of Pharmacology 2003, 463, page 145-161).
  • 7-GeranyI-oxycoumarin was evaluated at 3, 10 and 30 mg/kg, administered i.p. 30 min- utes before the test, and compared with a vehicle control group. 7-Geranyl-oxycoumarin was dissolved in a saline solution containing 3 weight-% DMSO and 3 weight-% Tween®
  • vehicle 80 (so called "vehicle”).
  • vehicle consisting of the saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 was administered intraperito- nally.
  • Fluoxetine 32 mg/kg, administered under the same experimental conditions, was used as a reference substance.
  • a soft gelatin capsule (500 mg) may be prepared comprising the following ingredients:
  • Two capsules per day for 3 months may be administered to a human adult for the treatment of mild chronic dysthymia.
  • a soft gelatin capsule (600 mg) may be prepared comprising the following ingredients:
  • Example 7 Preparation of a tablet
  • a 400 mg-tablet may be prepared comprising the following ingredients:
  • one tablet may be taken twice daily for 3 months.
  • the ready-to-drink soft drink contains ca. 30 mg Obliquin per serving (250 ml).
  • Example 9 Preparation of a fortified non baked cereal bar
  • Obliquin is premixed with skim milk powder and placed in a planetary bowl mixer. Corn ⁇ flakes and rice crispies are added and the total is mixed gently. Then the dried and cut ap ⁇ ples are added.
  • a first cooking pot sugar water and salt are mixed in the amounts given above (solution 1).
  • glucose invert and sorbitol syrup are mixed in the amounts given above (solution 2).
  • a mixture of baking fat, palmkernel fat, lecithin and emulsifier is the fat phase.
  • Solution 1 is heated to 110°C.
  • Solution 2 is heated to 113°C and then cooled in a cold water bath. Afterwards solution 1 and 2 are combined. The fat phase is melted at 75°C in a water bath.
  • the fat phase is added to the combined mixture of solu- tion 1 and 2.
  • Apple flavour and citric acid are added to the liquid sugar-fat mix.
  • the liquid mass is added to the dry ingredients and mixed well in the planetary bowl mixer.
  • the mass is put on a marble plate and rolled to the desired thickness.
  • the mass is cooled down to room temperature and cut into pieces.
  • the non baked cereal bar contains ca. 25 mg obliquin per serving (30 g). For general well-being and energizing 1-2 cereal bars may be eaten per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention refers to coumarin ethers of the formula (I), wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R3 is H, R1 and R2O together for the group -O-C(C(=CH2)CH3)H-CH2-O- or the group -C(H)=C(H)-C(CH3)2-O- or R2O and R3 together form the group -O-C(H)(C(CH3)2(H)-O-C(O)CH3)-CH2-, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.

Description

Novel agents for preventing and treating disorders connected to impaired neurotransmis¬ sion
The present invention refers to coumarin. ethers for use as medicaments, especially for the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant materials and extracts containing such coumarin ethers and their uses.
It is well known that impaired neurotransmission, e.g. low neurotransmitter levels, is con- nected to mental diseases such as depression.
Compounds that increase neurotransmitter levels in the brain and thus enhance their trans¬ mission, exhibit therefore antidepressant properties as well as beneficial effects on a vari¬ ety of other mental disorders ("Neurotransmitters, drugs and brain function" R.A. Webster (ed), John Wiley & Sons, New York, 2001, p. 187-211, 289-452, 477-498). The main neu¬ rotransmitters are serotonin, dopamine, noradrenaline (= norepinephrine), acetylcholine, glutamate, gamma-amino-butyric acid, as well as neuropeptides. Increase in neurotrans¬ mission is achieved by increasing the concentration of the neurotransmitter in the synaptic cleft thus making it available for increased or prolonged neurotransmission through inhibi- tion of re-uptake into the pre-synaptic nerve end, or by preventing neurotransmitter catabo- lism by inhibition of degrading enzymes such as monoaminooxidase A and B.
Tricyclic antidepressant compounds (TCAs) such as imipramine, amitriptyline, and clomipramine e.g. inhibit the re-uptake of serotonin and noradrenaline. They are widely regarded as among the most effective antidepressants available, but they have a number of disadvantages because they interact with a number of brain receptors, e.g. with cholinergic receptors. Most importantly, TCAs are not safe when taken in overdose, frequently show¬ ing acute cardiotoxicity.
Another class of antidepressant drugs are the so-called SSRIs (selective serotonin re¬ uptake inhibitors) including fluoxetine, paroxetine, sertraline, citalopram, fluvoxamine that
Best&tfgungskopϊθ block the serotonin transporter (SERT), a high affinity sodium chloride-dependent neuro¬ transmitter transporter that terminates serotonergic neurotransmission by uptake of sero¬ tonin. They have been proven as effective in the treatment of depression and anxiety, and are usually better tolerated than TCAs. These medications are typically started at low dos- ages and may be increased until they reach a therapeutic level. A common side effect is nausea. Other possible side effects include decreased appetite, dry mouth, sweating, infec¬ tion, constipation, yawn, tremor, sleepiness and sexual dysfunction.
In addition, compounds that prevent the catabolism of neurotransmitters more broadly by inhibiting the monoaminooxidases (MAOs) A and B exhibit antidepressant effects. MAOs catalyse the oxidation of amino group containing neurotransmitters such as serotonin, noradrenaline, and dopamine.
Furthermore, modulators of neurotransmission exert pleiotropic effects on mental and cog- nitive functions.
There is a need for compounds for the treatment or prevention of mental diseases and/or disorders which do not show the negative side effects of known antidepressants. Many pa¬ tients are interested in alternative therapies which could minimize the side effects associ- ated with high-dose of drugs and yield additive clinical benefits. Severe depression is a long lasting and recurring disease, which is usually poorly diagnosed. Furthermore many patients suffer from mild or middle severe depression. Thus, there is an increasing interest in the development of compounds as well as pharmaceutical and/or dietary compositions that may be used to treat mental diseases/disorders or to prevent the development of mental diseases/disorders such as depression in people at risk, and to stabilize mood.
According to the present invention this demand is met with coumarin ethers of the formula I,
Figure imgf000003_0001
wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7- dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11- acetyloxy-SJJlJl-tetramethyl-undeca^J-dien-lO-on-yl, R3 is H, R1 and R2O together form the group -O-C(C(=CH2)CH3)H-CH2-O- or the group -C(H)=C(H)-C(CH3)2-O- or R2O and R3 together form the group -O-C(H)(C(CH3)2(H)-O-C(O)CH3)-CH2-.
Thus, in one aspect the invention relates to a coumarin ether of the formula I with the defi¬ nitions of R1, R2 and R3 as given above, preferably to the coumarin ether wherein R1 and R2O together form the group -O-C(C(=CH2)CH3)H-CH2-O-, more preferably to obliquin, most preferably to (S)-obliquin, for use as medicament, particularly for use as medicament for the treatment of a disorder connected to impaired neurotransmission.
In another aspect, the invention relates to the use of a coumarin ether of the formula I as defined above for the manufacture of a composition for the treatment of a disorder con¬ nected to impaired neurotransmission, particularly for the manufacture of an antidepres¬ sant, a mood improver, a stress reliever, a condition improver, a reducer of anxiety and/or a reducer of obsessive-compulsive behaviour.
In still another aspect, the invention relates to a dietary composition containing at least one coumarin ether of the formula I as defined above as well as to a pharmaceutical composi¬ tion containing at least one coumarin ether of the formula I as defined above and a conven¬ tional pharmaceutical carrier.
Further, the invention relates to a method for the treatment of a disorder connected to im¬ paired neurotransmission in animals including humans, said method comprising adminis¬ tering an effective dose of a coumarin ether of the formula I as defined above to animals including humans which are in need thereof.
Animals in the context of the present invention include humans and encompass mammals, fish and birds. Preferred "animals" are humans, pet animals and farm animals. Examples for pet animals are dogs, cats, birds, toy fish, guinea pigs, (jack) rabbits, hares and ferrets. Examples for farm animals are fish, pigs, horses, ruminants (cattle, sheep and goat) and poultry.
In a preferred aspect of the present invention the coumarin ether of the formula I is selected from the group consisting of obliquin (compound of the formula It; see Fig. 1), xanthyletin (compound of the formula HI; see Fig. 1), suberosin (compound of the formula IV; see Fig. 1), 7-geranyloxycoumarm (compound of the formula V; see Fig. 1), ό'-dehydromarmin (compound of the formula VI; see Fig. 1), geiparvarin (compound of the formula VHI; see Fig. 1), O-acetylcolumbianetin (compound of the formula IX; see Fig. 1) and the com¬ pound of the formula VQ (see Fig. 1). More preferably the coumarin ether of the formula I is obliquin, most preferably the coumarin ether of the formula I is (5)-obliquin.
The term "coumarin ether of the formula I" also encompasses any material or extract of a plant containing such a coumarin ether of the formula I, especially any material or extract of a plant containing at least 90 weight-% of such a coumarin ether of the formula I based on the total weight of the plant material or extract. The terms "material of a plant" and "plant material" used in the context of the present invention mean any part of a plant.
"Obliquin" means the racemic mixture as well as pure R-obliquin or pure S-obliquin or any mixture of them. Obliquin can be isolated from plants like, but not limited to, Cedrelopsis grevei, Ptaeroxylon obliquum, Leontopodium alpinum, Helichrysum ssp., Ifloga spicata, Nidorella anomala, Cneorum tricoccum, Phaenocoma prolifera and Cedrelopsis microfo- liata (Journal of Natural Products 2002, 65, 1349-1352). Therefore, any material or extract of these plants or any other plant material or extract con¬ taining obliquin is also encompassed by this expression. "Obliquin" means both "natural" (isolated) and "synthetic" (manufactured) obliquin.
Obliquin's synthesis is described in J. Chem. Soc. (C) 1969, 526-531, as well as in Phyto- chemistry 1973, 12, 726-727.
7-Geranyloxycoumarin, also called "aurapten", can be isolated from plants like the follow¬ ing, but not limited to Citrus ssp., Aegle martnelos, Poncirus trifoliata, Afraegle panicu- lata, Severinia buxifolia, Atalantia monophylla, Ptelea trifoliata and Fortunella hindsii. Therefore, any material or extract of these plants or any other plant material or extract con¬ taining 7-geranyloxycoumarin is also encompassed by this expression. "7-Geranyloxy- coumarin" means both "natural" (isolated) and "synthetic" (manufactured) 7-geranyloxy¬ coumarin.
7-Geranyloxycoumarin can be prepared according to Tetrahedron Letters, 28(23), 2579-82; 1987.
Suberosin can be isolated from plants like the following, but not limited to Plumbago zey- lanica, Seseli ssp., Heracleum candicans, Citrus ssp., Prangos lipskyi and Prangos lo- phoptera. Therefore, any material or extract of these plants or any other plant material or extract containing suberosin is also encompassed by this expression. "Suberosin" means both "natural" (isolated) and "synthetic" (manufactured) suberosin.
Suberosin's synthesis is described in several articles, i.e. in Journal of the Chemical Soci¬ ety, Chemical Communications 1986? 16, 1264-1266.
The compound of formula VII (CAS [374702-57-5]) can be isolated from Ferula tadshi- korum and other plants. Therefore, any material or extract of these plants or any other plant material or extract containing the compound of formula VII is also encompassed by this expression. "Compound of formula VH" means both "natural" (isolated) and "synthetic" (manufactured).
6*-Dehydromarrnin can be isolated from the fruit of Geijera parviflora and other plants. Therefore, any material or extract of these plants or any other plant material or extract con¬ taining 6'-dehydromarmin is also encompassed by this expression. "6'-Dehydromarmin" means both "natural" (isolated) and "synthetic" (manufactured) 6'-dehydromarmin.
Geiparvarin can be isolated from the leaves of Geijera parviflora and other plants. There- fore, any material or extract of these plants or any other plant material or extract containing geiparvarin is also encompassed by this expression. " Geiparvarin" means both "natural" (isolated) and "synthetic" (manufactured) geiparvarin. Geiparvarin can be prepared according to the process described in Journal of Organic Chemistry 1985, 50(21), 3997-4005 or in Bioorganic & Medicinal Chemistry Letters 2002, 12(24), 3551-3555.
(>S)-O-Acetylcoluπibianetin can be isolated from plants like, but not limited to Cnidium monnieri and Angelica ssp. Therefore, any material or extract of these plants is also en¬ compassed by this expression. "O-Acetylcolumbianetin " means both "natural" (isolated) and "synthetic" (manufactured) O-acetylcolumbianetin.
Beside the (pure) compounds obliquin, xanthyletin, 7-geranyloxycoumarin, suberosin, 6'- dehydromarmin, geiparvarin, O-acetylcolumbianetin and the compound of the formula VII especially preferred are plant materials and plant extracts containing at least 90 weight-% of these compounds based on the total weight of the plant material/extract.
According to the present invention not only the coumarin ethers of formula I themselves, with the definitions of R1, R2 and R3 and the preferences as given above, but also plant ma¬ terials and extracts containing them, as well as dietary and pharmaceutical compositions containing them can be used as medicament, especially for the treatment of a disorder con¬ nected to impaired neurotransmission.
The dietary compositions according to the present invention may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsi- fiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (sol¬ vents), flowing agents, taste masking agents, weighting agents, jellyfying agents, gel form¬ ing agents, antioxidants and antimicrobials.
The term "dietary compositions" comprises any type of nutrition such as (fortified) food/feed and beverages including also clinical nutrition, and also dietary supplements.
Beside a pharmaceutically acceptable carrier and at least one coumarin ether of the formula I with the definitions of R1, R2 and R3 and the preferences as given above, the pharmaceu¬ tical compositions according to the present invention may further contain conventional pharmaceutical additives and adjuvants, excipients or diluents, including, but not limited to, water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like. The carrier material can be organic or inorganic inert carrier material suitable for oral/paren- teral/injectatøe administration.
The dietary and pharmaceutical compositions according to the present invention may be in any galenic form that is suitable for administrating to the animal body including the human body, especially in any form that is conventional for oral administration, e.g. in solid form such as (additives/supplements for) food or feed, food or feed premix, fortified food or feed, tablets, pills, granules, dragees, capsules, and effervescent formulations such as pow¬ ders and tablets, or in liquid form such as solutions, emulsions or suspensions as e.g. bev¬ erages, pastes and oily suspensions. The pastes may be filled into hard or soft shell cap- sules, whereby the capsules feature e.g. a matrix of (fish, swine, poultry, cow) gelatin, plant proteins or ligninsulfonate. Examples for other application forms are forms for trans¬ dermal, parenteral or injectable administration. The dietary and pharmaceutical composi¬ tions may be in the form of controlled (delayed) release formulations.
Examples of food are dairy products such as yoghurts.
Examples of fortified food are cereal bars, bakery items such as cakes and cookies.
Beverages encompass non-alcoholic and alcoholic drinks as well as liquid preparations to be added to drinking water and liquid food. Non-alcoholic drinks are e.g. soft drinks, sport drinks, fruit juices, lemonades, teas and milk based drinks. Liquid food are e.g. soups and dairy products (e.g. muesli drinks).
The coumarin ethers of formula I with the definitions of R1, R2 and R3 and the preferences as given above can be used for the manufacture of medicaments for the treatment of a dis¬ order connected to impaired neurotransmission. In the context of this invention "treatment" also encompasses co-treatment as well as prevention. "Prevention" can be the prevention of the first occurrence (primary prevention) or the prevention of a reoccurence (secondary prevention).
Thus, the present invention is also directed to a method for the prevention of a disorder connected to impaired neurotransmission in animals including humans, said method com¬ prising administering an effective dose of a coumarin ether of the formula I with the defini¬ tions of R1, R2 and R3 and the preferences as given above to animals including humans which are in need thereof. In this regard an effective dose of a coumarin ether of the for- mula I with the definitions of R1, R2 and R3 and the preferences as given above may espe¬ cially be used for maintaining the mental well-being, for maintaining a balanced cognitive function, for helping to reduce the risk of mood swings, for helping to retain a positive mood and for supporting cognitive wellness.
In the context of this invention the term "disorder" also encompasses diseases.
Medicaments for the treatment of disorders connected to impaired neurotransmission en¬ compass antidepressants, mood improvers, stress relievers, condition improvers, anxiety reducers and obsessive-compulsive behaviour reducers. They all improve, enhance and support the physiological neurotransmission, especially in the central nervous system, and therefore alleviate mental malfunction.
Antidepressants are medicaments for treating mental, behavioural and emotional/affective, neurotic, neurodegenerative, eating and stress related disorders such as e.g. unipolar de- pression, bipolar depression, acute depression, chronic depression, subchronic depression, dysthymia, postpartum depression, premenstrual dysphoria/syndrom (PMS), climacteric depressive symptoms, aggression, attention deficit disorders (ADS), social anxiety disor¬ ders, seasonal affective disorders, anxiety (disorders), fibromyalgia syndrome, chronic fa¬ tigue, sleep disorders (insomnia), post-traumatic stress disorders, panic disorders, obses- sive compulsive disorders, restless leg syndrome, nervousness, migraine/primary head¬ aches and pain in general, emesis, bulimia, anorexia nervosa, binge eating disorder, gastro¬ intestinal disorders, burn out syndrome, irritability and tiredness. Antidepressants can also be used for (the manufacture of compositions for) primary and secondary prevention and/or the treatment of neurocognitive impairment. Furthermore they are also effective in the treatment of depressive symptoms or other symptoms related to disturbed neurotransmission occurring as comorbidity in chronic diseases such as cardio- vascular diseases, strokes, cancer, Alzheimer disease, Parkinson disease, and others.
The coumarin ethers of the formula I with the definitions of R1, R2 and R3 and the prefer¬ ences as given above as well as plant materials and plant extracts (essentially) containing them and dietary/pharmaceutical compositions containing them are thus suitable for the treatment of animals including humans.
Especially pet animals and farm animals can be in conditions in need of enhanced or im¬ proved neurotransmission. Such conditions e.g. occur after capture or transport or with housing, when the animals develop analogous disorders and are distressed or aggressive, or display stereotypic behaviour, or anxiety and obsessive-compulsive behaviour.
Thus, the coumarin ethers of the formula I with the definitions of R , R and R and the preferences as given above can be used in general as antidepressants for animals including humans, preferably for humans, pet animals and farm animals.
In a further embodiment of the present invention the coumarin ethers of the formula I with the definitions of R1, R2 and R3 and the preferences as given above find use as mood im¬ prover in general as well as for the manufacture of compositions for such use (plant mate¬ rials/extracts; dietary/pharmaceutical compositions). "Mood improver" or "emotional well- ness booster" means that the mood of a person treated with it is enhanced, that the self es¬ teem is increased and/or that negative thoughts and/or negative tension are/is reduced. It also means the emotions are balanced and/or that the general, especially the mental, well being is improved or maintained, as well as that the risk of mood swings is (helped to be) reduced and that the positive mood is (helped to be) retained.
Moreover, coumarin ethers of the formula I with the definitions of R1, R2 and R3 and the preferences as given above as well as compositions comprising an effective dose of them are useful for the treatment, prevention and the alleviation of stress related symptoms, for the treatment, prevention and alleviation of symptoms related to working overload, exhaus- tion and/or burn out, for the increase of the resistance or tolerance to stress and/or to favor and facilitate the relaxation in normal healthy individuals i.e. such compositions have an effect as "stress reliever".
Furthermore, coumarin ethers of the formula I with the definitions of R , R and R and the preferences as given above as well as compositions comprising an effective dose of them are useful for the treatment, prevention and alleviation of anxiety and obsessive- compulsive behaviour in humans and animals.
A further embodiment of the present invention relates to the use of coumarin ethers of the formula I with the definitions of R1, R2 and R3 and the preferences as given above and to the use of compositions containing them (plant extracts; dietary/pharmaceutical composi¬ tions) as "condition improver", i.e. as means to reduce irritability and tiredness, to reduce or prevent or alleviate physical and mental fatigue, to favour undisturbed sleep, that is to act against insomnia and sleep disorders and to improve sleep, and to increase energy in more general terms, especially to increase the brain energy production, in diseased or nor¬ mal healthy individuals. Moreover for cognition improvement in general, and especially for maintenance or improvement of attention and concentration, of the memory and of the capacity for remembering, of the learning ability, of the language processing, of problem solving and of intellectual functioning; for improvement of the short-term memory; for in¬ creasing the mental alertness; for enhancing the mental vigilance; for reducing the mental fatigue; for supporting cognitive wellness, for maintaining balanced cognitive function, for the regulation of hunger and satiety as well as for the regulation of motor activity.
The present invention not only refers to coumarin ethers of the formula I with the defini¬ tions of R1, R2 and R3 and the preferences as given above and their compositions (i.e. plant extracts essentially containing them; dietary/pharmaceutical compositions containing them) for use as medicaments, especially for the treatment of disorders connected to im¬ paired neurotransmission, but also for the methods for the treatment of such disorders themselves, as already mentioned above.
In an especially preferred embodiment of such method pet animals or farm animals whose disorders are associated with housing, capture or transport are treated and which may ap¬ pear in form of anxiety or obsessive-compulsive behaviour. For humans a suitable daily dosage of a coumarin ether of the formula I, with the definition for R1, R2 and R3 and the preferences as given above, for the purposes of the present inven¬ tion may be within the range from 0.001 mg per kg body weight to about 20 mg per leg body weight per day. More preferred is a daily dosage of about 0.01 to about 10 mg per kg body weight, and especially preferred is a daily dosage of about 0.05 to 5.0 mg per kg body weight. The amount of a plant material or plant extract containing such coumarin ether of the formula I can be calculated accordingly.
In solid dosage unit preparations for humans, the coumarin ether of the formula I, with the definition for R1, R2 and R3 and the preferences as given above, is suitably present in an amount from about 0.1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg per dosage unit.
In dietary compositions, especially in food and beverages for humans, the coumarin ether of the formula I, with the definition for R1, R2 and R3 and the preferences as given above, is suitably present in an amount of from about 0.0001 (1 mg/kg) to about 5 weight-% (50 g/kg), preferably from about 0.001 % (10 mg/kg)to about 1 weight-%, (10 g/kg) more pref¬ erably from about 0.01 (100 mg/kg) to about 0.5 weight-% (5 g/kg), based upon the total weight of the food or beverage.
In food and drinks in a preferred embodiment of the invention the amount of the coumarin ether of the formula I with the definitions of R1, R2 and R3 and the preferences as given above is 10 to 30 mg per serving, i.e. 120 mg per kg food or drink.
For animals excluding humans a suitable daily dosage of a coumarin ether of the formula I, with the definition for R1, R2 and R3 and the preferences as given above, for the purposes of the present invention may be within the range from 0.001 mg per kg body weight to about 1000 mg per kg body weight per day. More preferred is a daily dosage of about 0.1 mg to about 500 mg per kg body weight, and especially preferred is a daily dosage of about 1 mg to 100 mg per kg body weight.
The invention is illustrated further by the following examples. Examples
In example 1 a racemic mixture of obliquin obtained from MicroSource Discovery Sys¬ tems Inc, 21 George Washington Plaza, Gaylordsville, CT 06755 USA was used. It had a purity of > 96%. In examples 2 and 3 a racemic mixture of obliquin synthesized according to J. Chem. Soc. (C) 1969, 526-531 was used. Xanthyletin were obtained from Micro- source as well. 7-geranyloxycoumarin, 6'-dehydromarmin, geiparvarin, (iS)-O-acetylcolum- bianetin and suberosin were obtained from APIN Chemicals, 43d Milton Park, Abingdon, Oxon, OX14 4RU, United Kingdom. And the compound of the formula VII was obtained from InterBioScreen Ltd., Bistitutsky Prospect, 7a 142432 Chernogolovka, Russia.
Example 1: Serotonin uptake inhibition and labeled citalopram displacement by coumarin ethers of the formula I.
HEK-293 cells stably expressing the human serotonin re-uptake transporter (hSERT) were obtained from R. Blakely, Vanderbilt University, USA. The cells were routinely grown in Dulbeco's Modified Eagles Medium, purchased from Bioconcept, Allschwil, Switzerland containing 10% fetal calf serum, penicillin, streptomycin, L-glutamine and the antibiotic G418 and passaged by trypsinisation.l day prior to the assay cells were seeded in the above mentioned medium. Immediately prior to the assay the medium was replaced by Krebs Ringers bicarbonate buffer, purchased from Sigma Chemicals Ltd., supplemented with 35 μM pargyline, 2.2 mM CaCl2, 1 mM ascorbic acid and 5 mM N-2-hydroxyethylpiperazine- N'-2-ethanesulfonic acid (buffer called "Hepes"). Serotonin uptake into the cells was de¬ termined by addition of radio-labeled (3H) serotonin (Amersham Biosciences GE Health¬ care, Slough, UK) to a concentration of 20 nM, and incubation for 30 minutes at room temperature. Following removal of unincorporated label by gentle washing three times with the above buffer, incorporated serotonin was quantified by liquid scintillation count¬ ing.
Membranes containing hSERT were prepared from the above cell line according to Galli et al, Journal of Experimental Biology 1995, 198, 2197-2212. 3 μg of membrane protein and 0.8 mg of wheat germ aglutinin coated SPA® (scintillation proximity assay) beads (Amer¬ sham Biosciences GE Healthcare, Slough, UK) per data point were mixed with radio¬ labeled (3H) citalopram (Amersham Biosciences GE Healthcare, Slough, UK) until a final concentration of 3.3 nM in 5OmM Tris-HCl, 300 mM NaCl (pH 7.4). After incubation for 18 hours at room temperature, the bound citalopram was quantified by liquid scintillation counting.
The effect of the coumarin ethers of formula I on the serotonin uptake and the citalopram binding was determined by its inclusion in the assay at a range of concentrations between 0.03 and 100 μM for 10 minutes prior to and during the addition of (3H) serotonin / citalo¬ pram. Serotonin uptake via the transporter and citalopram binding were both inhibited by the coumarin ethers of formula I in a dose dependent manner. The calculated inhibition constants Kj, derived from the measured IC50 using the Cheng - Prusoff equation (Y.C. Cheng, W.H. Prusoff, Biochem. Pharmacol. 1973, 22, p. 3099 - 3108), for inhibition of serotonin uptake and citalopram binding by coumarin ethers of the formula I are shown in Table 1.
Table 1: Inhibition constants for inhibition of serotonin uptake into transfected HEK-293 cells and displacement of labeled citalopram from hSERT containing membranes by cou¬ marin ethers of formula I.
Figure imgf000014_0001
If one experiment was carried out twice or several times the average value was taken. Example 2: Monoaminooxidase inhibition by obliquin.
From a stock solution of 0.0405 g of racemic obliquin (92.5%; equal to 37.5 mg of pure compound) in 750 μl of dimethylsulfoxide (DMSO), working solutions were prepared with a concentration of obliquin of 4 • 10"4M in reaction buffer (0.05 M sodium phosphate, pH 7.4, 0.2% DMSO). The final concentrations of obliquin in the test system were 10'4 M, 10"5 M, 10"6 M, 10-7 M. For determining the inhibition of monoaminoxidases' activity, the Amplex Red Monoam- ine Oxidase Assay Kit (Molecular Probes Nr._A-12214, Colorimetric version) was con¬ ducted according to manufacturers instructions.
As substrates for MAO-A enzyme (Sigma Nr. M7316) p-tyramine and as substrate for MAO-B enzyme (Sigma Nr. M7441) benzylamine were used. The concentration of MAO- A enzyme was 8 Units/ml, and that of MAO-B 4 Units/ml in the working solution.
MAO-A and MAO-B Assay, colorimetric version:
For the assay, 50 μl of each working solution (see above) were used. As control solution, the obliquin containing working solution was replaced by 50 μl of the reaction buffer.
50 μl of diluted MAO-A with a final concentration of 2 Units/ml and 50 μl of diluted MAO-B with a final concentration of 1 Unit/ml, respectively, were added.
100 μl of the Amplex solution containing horseradish peroxidase (2U/ml) and the substrate tyramine (for MAO-A) or the substrate benzylamine (for MAO-B) were added. To allow a subtraction of the background absorption a mixture of 100 μl of the Amplex solution and 100 μl of the reaction buffer was measured as a "blank".
The samples were incubated at room temperature in the dark for 1 hour, and then the ex¬ tinction at 535 nm determined in a Softmax Microplate photometer (Molecular Device).
The results are presented in Table 2 and 3. Table 2: Inhibition of MAO-A with increasing concentrations of obliquin.
Figure imgf000016_0001
Table 3: Inhibition of MAO-B with increasing concentrations of obliquin.
Figure imgf000016_0002
Thus obliquin showed MAO inhibition with a higher specificity for MAO-B than for MAO-A.
Example 3; Porsolt's swim test
The "Behavioural Despair Test" or "Porsolt's Forced Swim Test" is a validated animal model for depression (see T. Nagatsu, NeuroToxicology 2004, 25, 11-20, especially p. 16, right column in the middle, in combination with Porsolt et al., Arch. Int. Pharmacodyn. 1977, 229, 327-336). It responds to enhancement of the transmission of several neuro¬ transmitters including serotonine, dopamine and noradrenaline.
The test, which detects antidepressant activity, was carried out as described by Porsolt et al. in Arch. Int. Pharmacodyn. 1977, 229, 327-336. Mice which are forced to swim in a situation from which they cannot escape rapidly become immobile. Antidepressants de¬ crease the duration of immobility.
Mice were individually placed in a cylinder (Height = 24 cm, Diameter = 13 cm) contain- ing 10 cm water (22°C) from which they could not escape. The mice were placed in the water for 6 minutes and the duration of immobility during the last 4 minutes was meas¬ ured.
10 mice were studied per each of the four groups. The test was performed blind, i.e. the person carrying out the experiment was different from the person injecting the mice and didn't thus know to which of the four groups each mouse belonged.
Obliquin was evaluated at 3 doses each: at 10, 30, and 80mg/kg body weight, administered intraperitonally 30 minutes before the test, and compared with a control group. The thus administered obliquin was dissolved in a saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 (so called "vehicle"). To the control group the vehicle consist- ing of the saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 was administered intraperitonally.
Data were analyzed by comparing the treated groups with the control group using the un¬ paired Student's T tests and Analysis of Variance (ANOVA). They are presented in Table 4.
Table 4: Reduction of "immobility time" with increasing concentrations of obliquin.
Figure imgf000017_0001
* significantly different (p< 0.01, Student's T test) compared to the control group Thus, with obliquin the immobility time was significantly reduced by 25% in the highest dose group. Overall, there was a significant dose dependent effect of obliquin (ANOVA p<0.05).
Example 4: Marble Burying Test as test for anxiety like or obsessive compulsive behaviour
"Defensive burying" behaviour was demonstrated by rats burying noxious objects, such as drinking spouts filled with a unpleasant-tasting liquid (Wilkie et al., Journal of the Ex- perimental Analysis of Behavior 1979, 31, page 299-306) or shock prods (Pinel and Treit, Journal of Comparative and Physiological Psychology 1978, 92, page 708-712). The mar¬ ble burying test was devised as a modification of such a test. Poling et al. (Journal of the Experimental Analysis of Behavior 1981, 35, page 31-44) exposed rats to individual cages each containing 25 marbles, daily for 10 or 21 consecutive days. The number of marbles buried, on each day of the 10 d period, or 24 h after the 21 d exposure, were counted. The authors reported that the burying of marbles was not determined by novelty, or due to any noxious stimuli.
Marble burying behaviour by mice is reported to be sensitive to a range of minor (e.g. di- azepam) and major (e.g. haloperidol) tranquilisers (Broekkamp et al., Eur J Pharmacol.
1986, 126, page 223-229), in addition to SSRIs (e.g. fluvoxamine, fluoxetine, citalopram), tricyclic antidepressants (e.g. imipramine, desipramine) and selective noradrenaline uptake inhibitors (e.g. reboxetine), at doses which do not induce sedation. The model may reflect either anxiety-like-or obsessive-compulsive- behaviour (see De Boer and Koolhaas, Euro- pean Journal of Pharmacology 2003, 463, page 145-161).
The method applied here follows that described by Broekkamp et al. (1986). Mice (n = 15 per treatment group) were individually placed in transparent plastic cages (33 x 21 x 18 cm) with 5 cm of sawdust on the floor and 25 marbles (diameter 1 cm) grouped in the cen- tre of the cage. A second, up-turned, cage served as a lid. The number of marbles covered by sawdust (by at least two-thirds) was counted at the end of the 30-minute test period. Tests were performed by investigators blind to the drug treatment protocol. Prior to testing, all test cages and marbles were "impregnated" by leaving 10 naive mice in each cage for 15 minutes.
7-GeranyI-oxycoumarin was evaluated at 3, 10 and 30 mg/kg, administered i.p. 30 min- utes before the test, and compared with a vehicle control group. 7-Geranyl-oxycoumarin was dissolved in a saline solution containing 3 weight-% DMSO and 3 weight-% Tween®
80 (so called "vehicle"). To the control group the vehicle consisting of the saline solution containing 3 weight-% DMSO and 3 weight-% Tween® 80 was administered intraperito- nally. Fluoxetine (32 mg/kg), administered under the same experimental conditions, was used as a reference substance.
Data were analysed by comparing treated groups with vehicle control using unpaired Stu¬ dent's t-tests.
Results: Table 5: Effects of 7-geranyl-oxycoumarin and fluoxetine in the marble burying test in mice
Figure imgf000019_0001
n=15; Student's t test: * = p < 0.05; *** = p < 0.001.
7-Geranyl-oxycoumarin (3, 10 and 30 mg/kg), administered intraperitonally ("i.p.") 30 minutes before the test, dose-dependently decreased the number of marbles covered, as compared with the vehicle control (-27%, p < 0.05, -39%, p < 0.05 and -74%, p < 0.001, respectively). Fluoxetine (32 mg/kg i.p.), administered under the same experimental conditions, nearly abolished marble burying, as compared with the vehicle control (-98%, p < 0.001).
These results show that 7-geranyl-oxycoumarin has a similar activity for reduction in anxi- ety/obsessive-compulsive behaviour like the SSRI fluoxetine.
Example 5; Preparation of a soft gelatin capsule
A soft gelatin capsule (500 mg) may be prepared comprising the following ingredients:
Figure imgf000020_0001
Two capsules per day for 3 months may be administered to a human adult for the treatment of mild chronic dysthymia.
Example 6: Preparation of a soft gelatin capsule
A soft gelatin capsule (600 mg) may be prepared comprising the following ingredients:
Figure imgf000020_0002
One capsule per day preferably at the second half of the menstrual cycle may be taken for 14 days for the treatment of premenstrual syndrome and premenstrual dysphoric disorder. Example 7: Preparation of a tablet
A 400 mg-tablet may be prepared comprising the following ingredients:
Figure imgf000021_0001
For general well being, energizing and stress alleviation, one tablet may be taken twice daily for 3 months.
Example 8: Preparation of an instant flavoured soft drink
Figure imgf000021_0002
All ingredients are blended and sieved through a 500μm sieve. The resulting powder is put in an appropriate container and mixed on a turbular blender for at least 20 minutes. For preparing the drink, 125 g of the obtained mixed powder are taken and filled up with water to one liter of beverage.
The ready-to-drink soft drink contains ca. 30 mg Obliquin per serving (250 ml).
As a strenghtener and for general well being 2 servings per day (240ml) may be drunk. Example 9: Preparation of a fortified non baked cereal bar
Figure imgf000022_0001
Obliquin is premixed with skim milk powder and placed in a planetary bowl mixer. Corn¬ flakes and rice crispies are added and the total is mixed gently. Then the dried and cut ap¬ ples are added. In a first cooking pot sugar, water and salt are mixed in the amounts given above (solution 1). In a second cooking pot glucose, invert and sorbitol syrup are mixed in the amounts given above (solution 2). A mixture of baking fat, palmkernel fat, lecithin and emulsifier is the fat phase. Solution 1 is heated to 110°C. Solution 2 is heated to 113°C and then cooled in a cold water bath. Afterwards solution 1 and 2 are combined. The fat phase is melted at 75°C in a water bath. The fat phase is added to the combined mixture of solu- tion 1 and 2. Apple flavour and citric acid are added to the liquid sugar-fat mix. The liquid mass is added to the dry ingredients and mixed well in the planetary bowl mixer. The mass is put on a marble plate and rolled to the desired thickness. The mass is cooled down to room temperature and cut into pieces. The non baked cereal bar contains ca. 25 mg obliquin per serving (30 g). For general well-being and energizing 1-2 cereal bars may be eaten per day.

Claims

Claims
1. A dietary or pharmaceutical composition containing at least one coumarin ether of the formula I
Figure imgf000024_0001
wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (£/Z)~3,7- dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11- acetyloxy-3,7,ll,ll-tetramethyl-undeca-2,7-dien-10-on-yl, R3 is H, R1 and R2O together form the group -O-C(C(=CH2)CH3)H-CH2-O- or the group -C(H)=C(H)-C(CH3)Z-O- or R2O and R3 together form the group -O-C(H)(C(CH3)2(H)-O-C(O)CH3)-CH2-, pref¬ erably the coumarin ether wherein R1 and R2O together form the group -O- C(CC=CH2)CH3)H-CH2-O-, more preferably obliquin.
2. The dietary or pharmaceutical composition according to claim 1, wherein the coumarin ether of the formula I is selected from the group consisting of obliquin, xanthyletm, 7- geranyloxycoumarin, suberosin, 6'-dehydromarmm, geiparvarin, O-acetylcolumbianetin and the compound of the formula VH
Figure imgf000024_0002
3. The dietary composition according to claim 1 or 2 being in form of food such as dairy products (yoghurts), in form of fortified food such as cereal bars and bakery items such as cakes and cookies, in form of dietary supplements such as tablets, pills, granules, dragees, capsules, and effervescent formulations, in form of non-alcoholic drinks such as soft drinks, sport drinks, fruit juices, lemonades, teas and milk based drinks, in form of liquid food such as soups and dairy products (muesli drinks).
4. Use of the dietary composition according to any one of claims 1 to 3 or the pharmaceu¬ tical composition according to claim 1 or 2 as anti-depressant, mood improver, stress re¬ liever, condition improver, reducer of anxiety and/or reducer of obsessive-compulsive behaviour.
5. Coumarin ether of the formula I as defined in claim 1, for use as medicament.
6. The coumarin ether of the formula I as defined in claim 1 for use as medicament for the treatment of a disorder connected to impaired neurotransmission.
7. The coumarin ether of the formula I as defined in claim 1 for use according to claim 6 as antidepressant, mood improver, stress reliever, condition improver, reducer of anxiety and/or reducer of obsessive-compulsive behaviour.
8. The coumarin ether of the formula I according to any one of claims 5 to 7, wherein the coumarin ether is selected from the group consisting of obliquin, xanthyletin, 7- geranyloxycoumarin, suberosin, 6T-dehydromarmin, geiparvarin, O-acetylcolumbianetin and the compound of the formula VII
Figure imgf000025_0001
9. Use of a coumarin ether of the formula I as defined in claim 1 for the manufacture of a composition for the treatment of a disorder connected to impaired neurotransmission.
10. The use according to claim 9, wherein the composition is an antidepressant, a mood improver, a stress reliever, a condition improver, a reducer of anxiety and/or a reducer of obsessive-compulsive behaviour.
11. A method for the treatment and/or prevention of a disorder connected to impaired neu¬ rotransmission in animals including humans, said method comprising administering an ef¬ fective dose of a coumarin ether of the formula I as defined in claim 1 to animals including humans which are in need thereof.
12. The method according to claim 11, wherein the animal is a human, a pet animal or a farm animal.
PCT/CH2005/000621 2004-10-22 2005-10-21 Novel agents for preventing and treating disorders connected to impaired neurotransmission Ceased WO2006042441A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007537097A JP2008517879A (en) 2004-10-22 2005-10-21 Novel drugs for preventing and treating disorders related to neurotransmission disorders
US11/665,072 US8044094B2 (en) 2004-10-22 2005-10-21 Agents for preventing and treating disorders connected to impaired neurotransmission
DE602005012132T DE602005012132D1 (en) 2004-10-22 2005-10-21 NEW MEANS OF PROPHYLAXIS AND TREATMENT OF ILLNESSES ASSOCIATED WITH EMPIREED NEUROTRANSMISSION
EP05794149A EP1802298B1 (en) 2004-10-22 2005-10-21 Novel agents for preventing and treating disorders connected to impaired neurotransmission

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04025165.4 2004-10-22
EP04025165 2004-10-22

Publications (2)

Publication Number Publication Date
WO2006042441A2 true WO2006042441A2 (en) 2006-04-27
WO2006042441A3 WO2006042441A3 (en) 2006-07-13

Family

ID=36154615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2005/000621 Ceased WO2006042441A2 (en) 2004-10-22 2005-10-21 Novel agents for preventing and treating disorders connected to impaired neurotransmission

Country Status (9)

Country Link
US (1) US8044094B2 (en)
EP (1) EP1802298B1 (en)
JP (2) JP2008517879A (en)
KR (1) KR20070068400A (en)
CN (2) CN101703239A (en)
AT (1) ATE418980T1 (en)
DE (1) DE602005012132D1 (en)
ES (1) ES2320686T3 (en)
WO (1) WO2006042441A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100158A1 (en) * 2009-03-03 2010-09-10 Givaudan Sa Off-taste masking
WO2011108499A1 (en) * 2010-03-03 2011-09-09 株式会社エリナ Osteoblast differentiation promoter, pharmaceutical composition for promoting ossification, and health food containing auraptene analog as active ingredient
CN102267966A (en) * 2011-08-01 2011-12-07 华中科技大学 Substituted benzopyrone derivatives and application thereof
JP2022003339A (en) * 2017-01-13 2022-01-11 国立大学法人千葉大学 DGKδ knockout mouse and method using it

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802723B2 (en) * 2005-01-21 2014-08-12 Arkray, Inc. Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
JP5945861B2 (en) * 2011-09-29 2016-07-05 学校法人松山大学 Pharmaceutical composition and method for producing the same
CN108478568B (en) * 2018-02-01 2020-08-28 华中农业大学 Application of a kind of coumarin compound in the preparation of monoamine oxidase inhibitor
CN116650476B (en) * 2023-05-30 2025-09-09 南华大学附属第一医院 Compound, composition and application thereof in preparation of medicines for treating heart diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1770171C3 (en) * 1967-04-14 1979-08-30 Beecham Group Ltd., Brentford, Mddlesex (Grossbritannien) 2,2-Dimethyl-7-alkyl-4- (4-pyridyl) -2H-chromen-5-ols, process for their preparation and medicinal preparations containing these compounds
GB1497161A (en) * 1975-07-19 1978-01-05 Beecham Group Ltd Naphthyl derivatives
JPH04128224A (en) * 1989-11-28 1992-04-28 Sankyo Co Ltd Cerebral circulation metabolism-improving agent having coumarin ring
JP2004131432A (en) * 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation Malignant tumor suppressor
EP1588705A1 (en) * 2004-04-21 2005-10-26 INTE:LIGAND Software-Entwicklungs und Consulting GmbH Use of coumarin derivatives
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100158A1 (en) * 2009-03-03 2010-09-10 Givaudan Sa Off-taste masking
CN102413713A (en) * 2009-03-03 2012-04-11 奇华顿股份有限公司 Odor masking
CN102413713B (en) * 2009-03-03 2013-07-17 奇华顿股份有限公司 Odor masking
WO2011108499A1 (en) * 2010-03-03 2011-09-09 株式会社エリナ Osteoblast differentiation promoter, pharmaceutical composition for promoting ossification, and health food containing auraptene analog as active ingredient
JPWO2011108499A1 (en) * 2010-03-03 2013-06-27 株式会社エリナ Osteoblast differentiation-promoting agent, pharmaceutical composition for promoting bone formation, and functional food for health, containing aurapten-related compounds as active ingredients
US8729279B2 (en) 2010-03-03 2014-05-20 Erina Co., Inc. Agent for promoting osteoblast differentiation, pharmaceutical composition for promoting bone formation, and food for special dietary use containing auraptene analog as active ingredient
CN102267966A (en) * 2011-08-01 2011-12-07 华中科技大学 Substituted benzopyrone derivatives and application thereof
JP2022003339A (en) * 2017-01-13 2022-01-11 国立大学法人千葉大学 DGKδ knockout mouse and method using it
JP7152068B2 (en) 2017-01-13 2022-10-12 国立大学法人千葉大学 DGKδ knockout mouse and method using same

Also Published As

Publication number Publication date
KR20070068400A (en) 2007-06-29
EP1802298B1 (en) 2008-12-31
ATE418980T1 (en) 2009-01-15
EP1802298A2 (en) 2007-07-04
DE602005012132D1 (en) 2009-02-12
JP2013063974A (en) 2013-04-11
JP2008517879A (en) 2008-05-29
CN101703239A (en) 2010-05-12
US8044094B2 (en) 2011-10-25
US20070293563A1 (en) 2007-12-20
ES2320686T3 (en) 2009-05-27
CN101043886A (en) 2007-09-26
WO2006042441A3 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
US8552055B2 (en) Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses
EP2068863B1 (en) Ligustilide for the treatment of disorders of the central nervous system
JP2013063974A (en) Use of composition for purpose of manufacturing novel medicament for preventing and treating disorder connected to impaired neurotransmission
EP2099318B1 (en) Use of compositions containing carnosol and/or rosmanol
US20120149766A1 (en) Dietary and pharmaceutical compositions comprising a sage extract containing a mixture of tricyclic diterpenes and their derivatives and their uses
EP1930019A1 (en) Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005794149

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2853/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077009108

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580036244.4

Country of ref document: CN

Ref document number: 2007537097

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11665072

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005794149

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11665072

Country of ref document: US